Animal cells and systems

  • 제8권3호
  • /
  • Pages.197-203
  • /
  • 2004
  • /
  • 1976-8354(pISSN)
  • /
  • 2151-2485(eISSN)
한국통합생물학회 (The Korean Society for Integrative Biology)
권호 표지

Expression of CD30 in Testis and Epididymis of Adult Mice

  • Choo, Young-Kug (Divison of Biological Science, College of Natural Sciences, and Research Institute for Basic Sciences, Wonkwang University) ;
  • Nam, Sang-Yun (Department of Biological Science, School of Science and Technology, Jeonju University)
  • 발행 : 2004.09.01
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

CD30 is a member of tumor necrosis factor receptor (TNFR) superfamily and has pleiotropic functions including cell activation, proliferation, differentiation, and death, depending on cell types and stage of differentiation. Although CD30 expression has been described mainly in hematopoietic tissues, several types of nonhematopoietic tumors including embryonic carcinoma and germ-cell tumors express CD30. We examined CD30 distribution in the testis and epididymis from wild type and CD30-deficient mice. In the testis, spermatogonia, spermatocytes and Sertoli cells expressed CD30, but not in spermatids. Spermatogonia and spermatocytes near the basement membrane strongly reacted to anti-CD30. In the epididymis, CD30 expression was exclusively observed in luminal epithelia and some interstitial cells. Taken together, these results show a spatio-temporal regulation of CD30 expression in mouse testis and epididymis and suggest a possible role of CD30 in spermatogonia and spermatocytes.

키워드

참고문헌

  1. Amakawa R, Hakem A, Kundig TM, Matsuyama T, Simard JJ, Timms E, Wakeham A, Mittruecker HW, Griesser H, Takimoto H, Schmits R, Shahinian A, Ohashi P, Penninger JM, and Mak TW (1996) Impaired negative selection of T cells in Hodgkin's disease antigen CD30-deficient mice. Cell 84: 551-562 https://doi.org/10.1016/S0092-8674(00)81031-4
  2. Annunziato F, Galli G, Cosmi L, Romagnani P, Manetti R, Maggi E, and Romagnani S (1998) Molecules associated with human Th1 or Th2 cells. Eur Cytokine Netw 9: 12-16
  3. Barth S, Huhn M, Matthey B, Tawadros S, Schnell R, Schinkothe T, Diehl V, and Engert A (2000) Ki-4(scFv)-ETA', a new recombinant anti-CD30 immunotoxin with highly specific cytotoxic activity against disseminated Hodgkin tumors in SCID mice. Blood 95: 3909-3914
  4. Bengtsson A, Johansson C, Linder MT, Hallden G, van der Ploeg I and Scheynius A (1995) Not only Th2 cells but also Th1 and Th0 cells express CD30 after activation. Leukocyte Biol 58: 683-689 https://doi.org/10.1002/jlb.58.6.683
  5. Boekelheide K, Lee J, Shipp EB, Richburg JH, and Li G (1998) Expression of Fas system-related genes in the testis during development and after toxicant exposure. Toxicol Lett 102/103: 503-508 https://doi.org/10.1016/S0378-4274(98)00242-2
  6. Chomczynski P and Sacchi N (1987) Single-step method of RNA isolation by acid guanidium thiocyanate-phenol-chloroform extraction. Anal Biochem 161: 156-159 https://doi.org/10.1016/0003-2697(87)90021-2
  7. D'Elios MM, Romagnani P, Scaletti C, Annunziato F, Manghetti M, Mavilia C, Parronchi P, Pupilli C, Pizzolo G, Maggi E, Del Prete GF, and Romagnani S (1997) In vivo CD30 expression in human diseases with predominant activation of Th2-like T cells. J Leukocyte Biol 61: 539-544 https://doi.org/10.1002/jlb.61.5.539
  8. Durkop H, Latza U, Hummel M, Eitelbach F, Seed B, and Stein H (1992) Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease. Cell 68: 421-427 https://doi.org/10.1016/0092-8674(92)90180-K
  9. Eddy EM and O'Brien DA (1994) The spermatozoon. In: Knovil E and Neill JD (eds), The Physiology of Reproduction, Raven Press, New York, pp 29-77
  10. Ellis TM, Simms PE, Slivnick DJ, Jack HM, and Fisher RI (1993) CD30 is a signal-transducing molecule that defines a subset of human activated CD45RO+ T cells. J Immunol 151: 2380-2389
  11. Fawcett DW (2001) The mammalian spermatozoon. Dev Biol 44: 394-436 https://doi.org/10.1016/0012-1606(75)90411-X
  12. Graus F, Cordon-Cardo C, Houghton AN, Melamed MR, and Old LJ (1984) Distribution of the ganglioside GD3 in the human nervous system detected by R24 mouse monoclonal antibody. Brain Res 324: 190-194 https://doi.org/10.1016/0006-8993(84)90642-5
  13. Gruss HJ and Dower SK (1995) Tumor necrosis factor ligand superfamily: involvement in the pathology of malignant lymphomas. Blood 85: 3378-3404
  14. Gruss HJ, Boiani N, Williams DE, Armitage RJ, Smith CA and Goodwin RG (1994a) Pleiotropic effects of the CD30 ligand on CD30-expressing cells and lymphoma cell lines. Blood 83: 2045-2056
  15. Gruss HJ, DaSilva N, Hu ZB, Uphoff CC, Goodwin RG, and Drexler HG (1994b) Expression and regulation of CD30 ligand and CD30 in human leukemia-lymphoma cell lines. Leukemia 8: 2083-2094
  16. Hamann D, Hilkens CM, Grogan JL, Lens SM, Kapsenberg ML, Yazdanbakhsh M, and van Lier RA (1996) CD30 expression does not discriminate between human Th1- and Th2-type T cells. J Immunol 156: 1387-1391
  17. Herbst H, Stein H, and Niedobitek G (1993) Epstein-Barr virus and CD30+ malignant lymphomas. Crit Rev Oncolog 4: 191-239
  18. Hodges GF, Lenhardt TM, Secord AR, Rushin JM, and Cotelingam JD (1991) CD30 antigen expression. Am J Clin Pathol 95: 103
  19. Jung KY, Kim BH, Hwang MR, Cho JR, Kim HM, Lee YC, Kim CH, Kim JK, Kim BJ, and Choo YK (2001) Differential distribution of ganglioside GM3 in seminiferous tubule and epididymis of adult rats. Arch Pharmacal Res 24: 360-366 https://doi.org/10.1007/BF02975107
  20. Kurts C, Carbone FR, Krummel MF, Koch KM, Miller JF, and Heath WR (1999) Signalling through CD30 protects against autoimmune diabetes mediated by CD8 T cells. Nature 398: 341-344 https://doi.org/10.1038/18692
  21. Latza U, Foss HD, Durkop H, Eitelbach F, Dieckmann KP, Loy V, Unger M, Pizzolo G, and Stein H (1995) CD30 antigen in embryonal carcinoma and embryogenesis and release of the soluble molecule. Am J Pathol 146: 463-471
  22. Levi E, Pfeifer WM, and Kadin ME (2001) CD30-activationmediated growth inhibition of anaplastic large-cell lymphoma cell lines: apoptosis or cell-cycle arrest? Blood 98: 1630-1632 https://doi.org/10.1182/blood.V98.5.1630
  23. Mechtersheimer G and Moller P (1990) Expression of Ki-1 antigen (CD30) in mesenchymal tumors. Cancer 66: 1732-1737 https://doi.org/10.1002/1097-0142(19901015)66:8<1732::AID-CNCR2820660815>3.0.CO;2-5
  24. Meehan T, Schlatt S, O'Bryan MK, de Kretser DM and Loveland KL (2000) Regulation of germ cell and Sertoli cell development by activin, follistatin, and FSH. Dev Biol 220: 225-237 https://doi.org/10.1006/dbio.2000.9625
  25. Meng X, Lindahl M, Hyvonen ME, Parvinen M, de Rooij DG, Hess MW, Raatikainen-Ahokas A, Sainio K, Rauvala H, Lakso M, Pichel JG, Westphal H, Saarma M, and Sariola H (2000) Regulation of cell fate decision of undifferentiated spermatogonia by GDNF. Science 287: 1489-1493 https://doi.org/10.1126/science.287.5457.1489
  26. Opat S and Gaston JS (2000) CD30:CD30 ligand interactions in the immune response. Autoimmunity 33: 45-60
  27. Pallesen G and Hamilton-Dutoit SJ (1988) Ki-1 (CD30) antigen is regularly expressed by tumor cells of embryonal carcinoma. Am J Pathol 133: 446-450
  28. Papadopoulos N, Galazios G, Anastasiadis P, Kotini A, Stellos K, Petrakis G, Zografou G, Polihronidis A, and Tamiolakis D (2001) Human decidual cells can express the Hodgkin's cellassociated antigen Ki-1 (CD30) in spontaneous abortions during the first trimester of gestation. Clin Exp Obstet Gynecol 28: 225-228 https://doi.org/10.1016/S0889-8545(05)70198-4
  29. Paulli M, Berti E, Rosso R, Boveri E, Kindl S, Klersy C, Lazzarino M, Borroni G, Menestrina F, Santucci M and et al. (1995) CD30/Ki-1-positive Iymphoproliferative disorders of the skin-clinicopathologic correlation and statistical analysis of 86 cases: a multicentric study from the European Organization for Research and Treatment of Cutaneous Lymphoma Project Group. J Clin Oncol 13: 1343-1354
  30. Pera MF, Bennett W, and Cerretti DP (1998) CD30 and its ligand: possible role in regulation of teratoma stem cells. Apmis 106: 169-172; discussion 173 https://doi.org/10.1111/j.1699-0463.1998.tb01332.x
  31. Piris M, Brown DC, Gatter KC, and Mason DY (1990) CD30 expression in non-Hodgkin's lymphoma. Histopathology 17: 211-218 https://doi.org/10.1111/j.1365-2559.1990.tb00709.x
  32. Rivarola MA, Sanchez P, and Saez JM (1985) Stimulation of ribonucleic acid and deoxyribonucleic acid synthesis in spermatogenic cells by their coculture with Sertoli cells. Endocrinology 117: 1796-1802 https://doi.org/10.1210/endo-117-5-1796
  33. Romagnani S, Del Prete G, Maggi E, Chilosi M, Caligaris-Cappio F and Pizzolo G (1995) CD30 and type 2 T helper (Th2) responses. J Leukocyte Biol 57: 726-730 https://doi.org/10.1002/jlb.57.5.726
  34. Romagnani S (1995) Role for CD30 antigen in human T helper 2-type responses. Ciba Found Symp 195: 55-67
  35. Romagnani S (1996) Th1 and Th2 in human diseases. Clin Immunol Immunopathol 80: 225-235 https://doi.org/10.1006/clin.1996.0118
  36. Romagnani S, Parronchi P, D'Elios MM, Romagnani P, Annunziato F, Piccinni MP, Manetti R, Sampognaro S, Mavilia C, De Carli M, Maggi E, and Del Prete GF (1997) An update on human Th1 and Th2 cells. Int Arch Allergy Immunol 113: 153-156
  37. Schwab U, Stein H, Gerdes J, Lemke H, Kirchner H, Schaadt M, and Diehl V (1982) Production of a monoclonal antibody specific for Hodgkin and Sternberg-Reed cells of Hodgkin's disease and a subset of normal lymphoid cells. Nature 299: 65-67 https://doi.org/10.1038/299065a0
  38. Smith CA, Davis T, Anderson D, Solam L, Beckmann MP, Jerzy R, Dower SK, Cosman D, and Goodwin RG (1990) A receptor for tumor necrosis factor defines an unusual family of cellular and viral proteins. Science 248: 1019-1023 https://doi.org/10.1126/science.2160731
  39. Telford WG, Nam SY, Podack ER, and Miller RA (1997) CD30regulated apoptosis in murine CD8 T cells after cessation of TCR signals. Cell Immunol 182: 125-136 https://doi.org/10.1006/cimm.1997.1228
  40. Willers J, Dummer R, Kempf W, Kundig T, Burg G, and Kadin ME (2003) Proliferation of CD30+ T-helper 2 lymphoma cells can be inhibited by CD30 receptor cross-linking with recombinant CD30 ligand. Clin Cancer Res 9: 2744-2754